Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.34 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | 1 Parkinson's trial, 0 stopped | 1.00 |
| literature PubMed | 10 Parkinson's papers of 3,173 | 0.69 |
| pathways Reactome | 1 pathway; mostly other | 0.30 |
No case: the score is under the bar. Receipt 0928
Sealed predictions
- MVP in dopamine neurons, braak+0.11 (p 0.775) → -0.71 (p 0.032)receipt 0935
Swarm cases
receipt 0935: MVP in dopamine neurons, braak
- power
- full sample -0.21 (p 0.398, n 18), 95% CI -0.62 to +0.28. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.15 (p 0.544, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.17 (p 0.504, n 18). could be the mix.
- skeptic
- leave-one-out range -0.36 to -0.12, sign flips 0; without severely affected donors -0.21 (p 0.398, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.71 (p 0.0010, n 18) vs -0.21 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for MVP in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up MVP · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.22 p 0.424 (needs p < 0.0014)
Receipts
loading the receipts